FDA-TRACK Newsletter - January 5, 2022
FDA-TRACK Releases Interactive Reportable Food Registry Dashboard
Today, FDA-TRACK launches a new, interactive public data dashboard that allows anyone to view historical data from the Reportable Food Registry (RFR), an essential tool that the food industry uses to alert the FDA of dangerous food product. The new dashboard, which will be updated annually, makes it faster and easier to get better data from the RFR compared to the past. The RFR program helps our state and local partners better determine when to issue health alerts, take steps to remove harmful food from the market, and target enforcement efforts, such as sampling assignments.
A Faster and Easier Way to Obtain and Analyze Data from the FDA
Our new RFR public data dashboard contains 10 years of data from September 2009 to 2019 and covers 28 commodities and 20 food safety hazards. Unlike the past RFR annual reports previously used to publish data, the new dashboard allows users to interact with data points to gather more customized information at any time to find answers to their specific questions. Users can modify the graphs and charts and view trends based on selected commodities, hazards, and time frames.
In publishing this dashboard, the FDA is taking additional steps to increase public data access by including a downloadable, raw RFR data set to enable stakeholders to perform, their own analyses.
In modernizing how people can view and use RFR data, the interactive dashboard:
- Increase access and transparency with state and local partners who use the data to better workplan and determine how to target their own sampling assignments to concerns that are more common in their area;
- Allows industry to educate themselves on trends and identify areas where additional good manufacturing practices and preventive controls could better prevent future outbreaks or contamination in their products; and
- Offers a robust data set to researchers and others who are interested in studying the safety of our food system.
Overall, this will be a more efficient, less resource intensive process for FDA to provide data.